Sophiris reports patient death in prostate cancer trial

Sophiris Bio Inc. (NASDAQ:SPHS) reported a patient death in an open-label, U.S. and U.K. Phase IIb trial evaluating topsalysin (PRX302) to treat localized prostate cancer.

The company said it is evaluating the cause of death. The event occurred on the same day the patient received a second intraprostatic administration of topsalysin. The candidate is a recombinant proaerolysin protein activated by prostate-specific antigen (PSA; KLK3)...